Authority in the Field of Molecular Hydrogen
Together with Czech experts, we are officially launching the first clinical study in the Czech Republic focused on the use of molecular hydrogen in patients with mild cognitive impairment (MCI).
-
January 19, 2026 – Study launch
-
January 22, 2026 at 2:00 PM – Press conference at ČTK, Prague (media and partners are welcome)
As Professor Ohta stated:
“We want to work together with the team in the Czech Republic to establish a standardized pathway for regulatory registration in this field.”
Our objective is clear: to clinically validate, standardize, and advance the technology into the EU regulatory framework, and subsequently open the door to international collaboration, clinical partners, and strategic investors.
Full article here:
Scientific Authority from Japan, Professor Shigeo Ohta, Visits the Czech Republic: H2 Global Group Launches a Clinical Study with Molecular Hydrogen in the Czech Republic – Metro.cz